KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at ...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare ...

-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- ...

– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Independent Data Monitoring Committee recommended initiation of Cohort 2 at the increased dose of 12 mg/kg in the ELEVATE-44-201 study – – Cash runway expected into Q3 2027 with $296 million in cash, cash equivalents and marketable securities as of December 31, 2025 – BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeu ...

Core Insights - Aclaris Therapeutics reported positive interim results from its Phase 1a trials for the bispecific antibody ATI-052, indicating strong safety and tolerability, with complete results expected in Q2 2026 [1][3] - The company has initiated Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma, with top line results anticipated in the second half of 2026 [1][2] - Aclaris plans to file an Investigational New Drug (IND) application for its lead ITK inhibitor candidate, ATI-9494, in the second half of 2026 [1][12] Pipeline Developments - Positive interim results from the Phase 1a SAD/MAD trial of ATI-052 showed a favorable safety profile and robust target engagement, supporting potential extended dosing every three months [3][2] - Two Phase 1b POC trials for ATI-052 have been initiated, with results expected in the latter half of 2026 [3][2] - Planning for a Phase 2b program for ATI-052 is underway, targeting asthma and atopic dermatitis as initial indications [3] Financial Performance - Aclaris reported a net loss of $19.8 million for Q4 2025, a significant decrease from a net loss of $96.6 million in Q4 2024 [7] - Total revenue for Q4 2025 was $1.3 million, down from $9.2 million in Q4 2024, primarily due to a prior commercial milestone [8] - Research and development expenses increased to $16.6 million in Q4 2025 from $9.0 million in the prior year, driven by higher costs associated with product candidate development [9] Liquidity and Capital Resources - As of December 31, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $151.4 million, down from $203.9 million in 2024 [6][20] - The company believes its current financial resources will be sufficient to fund operations into the second half of 2028 [6]

Group 1 - The company is preparing for the potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review with a PDUFA target action date of September 18, 2026 [1] - The company plans to submit a New Drug Application (NDA) for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population in the first half of 2026 [1] - There is a planned submission for potential label expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population in the second half of 2026 [1] Group 2 - The company reported a strong financial position with an operating runway anticipated into 2029 [1] - The company outlined pipeline progress and reiterated key anticipated milestones during the fourth quarter and full year 2025 financial results [1]

Core Viewpoint - CASI Pharmaceuticals Inc. is transitioning to OTC Markets Group following a formal delisting from Nasdaq, which has led to a significant after-hours stock price increase of 24.48% to $0.25 [1][2]. Group 1: Delisting and Transition - The Nasdaq Hearings Panel issued a formal delisting determination due to CASI's failure to meet continued listing requirements, with trading suspension starting Thursday [2]. - CASI will not appeal the delisting decision and expects its ordinary shares to be quoted on OTC Markets Group, allowing trading to continue [2]. Group 2: Impact on Operations - CASI stated that the delisting carries "no significant impact" on its operations [3]. Group 3: Trading Metrics and Performance - CASI Pharmaceuticals has a market capitalization of $4.26 million, with a 52-week high of $3.08 and a 52-week low of $0.21 [4]. - The stock has experienced a decline of 91.13% over the past 12 months, closing the regular session down 74.06% at $0.21, currently at its annual low [4]. - The Relative Strength Index (RSI) of CASI stands at 18.40, indicating a negative price trend across all time frames according to Benzinga's Edge Stock Rankings [4][5].

Core Viewpoint - Pharming Group N.V. will report its preliminary (unaudited) financial results for Q4 and full year 2025 on March 12, 2026, along with a business update [1]. Group 1: Financial Reporting - The company will provide preliminary financial results for the fourth quarter and full year 2025 [1]. - A conference call and webcast for analysts and investors will be held on the same day at 13:30 CET/08:30 am EDT [1]. Group 2: Participation Details - Registration is required to participate in the conference call or to watch the live webcast [2]. - Dial-in information and a unique PIN will be provided upon registration, and questions will only be taken from dial-in attendees [3]. Group 3: Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for patients with rare and life-threatening diseases [5]. - The company is headquartered in Leiden, the Netherlands, with a significant number of employees based in the U.S. [5].

截至午间收盘，科创成长指数上涨1.5%，科创200指数上涨1.0%，科创100指数上涨0.9%，科创综指上涨0.6%，科创50指数上涨 0.1%。 | 科创50ETF易方达 低费率 | | | 588080 | | --- | --- | --- | --- | | 跟踪上证科创板50成份指数 | | | | | 该指数由科创板中市值大、流动性 | 截至午间收盘 | 该指数 | 该指数自2020年 | | 好的50只股票组成,"硬科技"龙 | 该指数涨跌 | 滚动市智率 | 发布以来估值分位 | | 头特征显著,半导体占比超65%, | | | | | 与医疗器械、软件开发、光伏设备 行业合计占比近80% | 0. 1% | 167. 3倍 | 95. 4% | | 【保要率 科创100ETF易方达 | | | 588210 | | 跟踪上证科创板100指数 | | | | | 该指数由科创板中市值中等且流动 性较好的100只股票组成,聚焦中 | 截至午间收盘 该指数涨跌 | 该指数 滚动市盈率 | 该指数 | | 小科创企业,电子、电力设备、医 | | | | | 药生物、计算机行业合计占比超 | | | ...

Core Viewpoint - InnoCare Pharma has made significant progress in clinical development, completing patient enrollment in multiple Phase III registrational trials for its cancer and autoimmune disease treatments [1] Group 1: Clinical Development Progress - The company completed patient enrollment in a Phase III trial for the BCL2 inhibitor mesutoclax (ICP-248) combined with BTK inhibitor orelabrutinib for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients [2] - InnoCare has also accelerated the clinical development of two novel TYK2 inhibitors, completing patient enrollment in the Phase III trial of soficitinib (ICP-332) for moderate to severe atopic dermatitis and in the Phase III trial of ICP-488 for psoriasis [4] - Additionally, patient enrollment has been completed in a Phase II trial of soficitinib for vitiligo, targeting various T-cell related autoimmune disorders [5] Group 2: Drug Mechanisms and Indications - Mesutoclax is a selective oral BCL2 inhibitor that restores normal apoptosis in cancer cells, aiming to provide deeper remission for treatment-naïve CLL/SLL patients [3] - Soficitinib is a potent TYK2 inhibitor being developed for multiple dermatological conditions, including atopic dermatitis, vitiligo, prurigo nodularis, CSU, and psoriasis [5][6] - ICP-488, an oral allosteric TYK2 inhibitor, blocks inflammatory cytokine signaling pathways, addressing autoimmune and inflammatory diseases [6] Group 3: Company Overview - InnoCare is a commercial stage biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases with unmet medical needs [7]